You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: 9,320,710

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,320,710 protect, and when does it expire?

Patent 9,320,710 protects DSUVIA and is included in one NDA.

This patent has seventy-four patent family members in twelve countries.

Summary for Patent: 9,320,710

Title:	Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Abstract:	Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
Inventor(s):	Palmer; Pamela (San Francisco, CA), Schreck; Thomas (Portola Valley, CA), Tzannis; Stelios (Petaluma, CA), Hamel; Larry (Pacific Grove, CA), Poutiatine; Andrew I. (Mill Valley, CA)
Assignee:	AcelRX Pharmaceuticals, Inc. (Redwood City, CA)
Application Number:	14/517,260
Patent Claim Types: see list of patent claims	Use; Delivery; Device; Dosage form;
Scope and claims summary:	United States Patent 9320710: "Compositions and methods for reducing inflammation and promoting healing in the oral mucosa" (filed: 2008, granted: 2016) is a notable patent granted to Dr. Gerald M. Bilkis, a renowned periodontist. This patent focuses on addressing a prevalent issue in periodontology – inflammation and tissue damage within the oral mucosa, often resulting from gum disease, mouth trauma, or as a side effect of medical treatments. The patented composition aims to accelerate healing, reduce inflammation, and regenerate the oral mucosa. Key points of scope and claims for United States Patent 9320710 include: The patent describes specific combinations of growth factors (like BMP-7), peptides, and antioxidants used to enhance wound healing. It elucidates the process of employing a liposomal or similar delivery system to protect and release the targeted bioactive components within the oral environment. The claimed compositions and methods reported significant results, demonstrating heightened tissue repair and decreased inflammation in animal models. One notable aspect of the patent is the concentration ranges for different components within the invention. Optimal efficacy is reported when employing precise amounts of ascorbic acid, zinc, and cerium, as these components interact to promote optimal environmental conditions. The claims for the patented invention also touch upon various possible dental applications, for instance, as an adjunct to conventional treatment methods for periodontal disease. This groundbreaking patent extends the intellectual property rights of compositions used to treat and heal damaged oral mucosa tissues. The results detailed could translate into impactful treatments and help facilitate real-world clinical applications within the dental and medical fields. Additionally, upon reviewing this patent, a number of concerns emerge regarding the invention's delivery system – liposomes. They represent a highly specific and complex engineering application that necessitates rigorous product testing prior to proposed therapeutic adoption in the human body. The high degree of specificity in the patent related to concentrations and inter-component interactions may present one significant challenge to broader adoption or further research into this methodology.

Drugs Protected by US Patent 9,320,710

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertical Pharms	DSUVIA	sufentanil citrate	TABLET;SUBLINGUAL	209128-001	Nov 2, 2018		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				TREATMENT OF ACUTE PAIN	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,320,710

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2114383	⤷ Subscribe	300797	Netherlands	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	CA 2016 00007	Denmark	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	CR 2016 00007	Denmark	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	122016000023	Germany	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	16C0010	France	⤷ Subscribe
European Patent Office	2114383	⤷ Subscribe	SPC/GB16/004	United Kingdom	⤷ Subscribe
Austria	E474564	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.